多巴胺D_3受体基因多态性与精神分裂症亚型及利培酮疗效相关性分析  

Association between polymorphism in the dopamine D_3 receptor gene and the sutypes of schizophrenia and efficacy of risperidone

作　　者：吕路线[1] 张红星[1] 郭素芹[1] 石玉中[1] 

机构地区：[1]河南新乡医学院第二附属医院,453003

出　　处：《上海精神医学》2005年第2期99-101,共3页Shanghai Archives of Psychiatry

摘　　要：目的探讨多巴胺D3受体(dopamineD3receptor,DRD3)基因第一外显子丝氨酸9甘氨酸(Ser9Gly)多态性与精神分裂症临床亚型、药物疗效的关联。方法241例汉族首发精神分裂症患者,采用限制性片段长度多态性(restrictionfragmentlengthpolymorphism,RFLP)技术测定基因型。分析判断基因多态性与精神分裂症的临床亚型、药物疗效的关联。结果精神分裂症各亚型Ser9Gly等位基因分布存在显著性差异(p<0.05)。利培酮疗效不同的患者间Ser9Gly等位基因多态性均无显著性差异。结论DRD3受体基因第一外显子Ser9Gly多态性可能与精神分裂症亚型相关,而与患者对药物的反应不相关。Objective: To investigate the association between the dopamine D 3 receptor (DRD 3 )gene Ser9Gly polymorphism and the subtypes of schizophrenia and the efficacy of risperidone. Methods: DRD 3 gene Ser9Gly polymorphism were detected with polymorase chain reaction in 241 inpatients with schizophrenia. Results:Distribution of allele was significant different among different subtypes of schizophrenia(P <0.05). There were no difference of Ser9Gly gene polymorphism in different responders to risperidone. Conclusion:There is an association between the DRD 3 Ser9Gly gene polymorphism and the subtypes of schizophrenia. No association exists between the Ser9Gly polymorphism and the efficacy of risperidone.

关 键 词：精神分裂症亚型 受体基因多态性 利培酮 相关性分析 限制性片段长度多态性 首发精神分裂症患者 receptor 多巴胺D3受体 等位基因多态性 第一外显子 显著性差异 等位基因分布 临床亚型 药物疗效 甘氨酸 丝氨酸 基因型 DRD 

分 类 号：R749.3[医药卫生—神经病学与精神病学] R681.02[医药卫生—临床医学]